Key result
Coadministration of the bradykinin B2 receptor antagonist icatibant attenuated the mean arterial blood pressure response to acute ACE inhibition with perindoprilat (P<0.0005).
Why the study?
Does coadministration of the bradykinin B2 receptor antagonist icatibant attenuate the blood pressure response to acute ACE inhibition with perindoprilat in normal men?
RCT (n=12)
Double-blind
Does coadministration of the bradykinin B2 receptor antagonist icatibant attenuate the blood pressure response to acute ACE inhibition with perindoprilat in normal men?
p-value: p=<0.0005
Bradykinin B2 receptor antagonism attenuates the acute blood pressure-lowering effect of ACE inhibition, demonstrating that bradykinin is involved in resting blood pressure control in humans.
No takes yet. Share an insight, caveat, or question.
Bradykinin contributes to acute ACE inhibitor blood pressure effects; confirms its role in human BP regulation and extends mechanistic research beyond angiotensin pathways.
Squire et al. (2000) conducted an RCT in Healthy volunteers (n=12). Icatibant coadministered with perindoprilat vs. Placebo was evaluated on Mean arterial blood pressure response (p=<0.0005). Coadministration of the bradykinin B2 receptor antagonist icatibant attenuated the mean arterial blood pressure response to acute ACE inhibition with perindoprilat (P<0.0005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: